We are very excited to be backing the founders of Neurofenix, Guillem Singla Buxarrais (CEO) and Dimitris Athanasiou (CTO), in their $7 million Series A raise! We’ve invested alongside our friends at Albion VC, as well as HTH.
Neurofenix is scaling neuro-rehabilitation. Neuro-rehabilitation is delivered to patients with degenerative diseases, acute trauma, or disorders of the nervous system. Existing approaches to neuro-rehabilitation are typically based on 1-1 therapy. Unfortunately, as in many other areas of healthcare, workforce shortages severely limit the ability to deliver care in an optimal way – leading to long waiting lists for treatment and insufficient length of therapy.
Neurofenix’s initial focus is on one of the leading causes of serious long-term disability in the US – stroke. In the last decade, major advances have been made in the acute management of stroke. Health systems including the NHS have implemented hyper-acute stroke pathways that ensure that once a potential cerebrovascular event is identified, the affected patient is transported to a specialist centre for imaging and intervention based on the well-established mantra ‘time is brain’. Based on best practice management, vessel occlusion can be reversed and brain function entirely restored, minimising long term neurological damage.
In spite of these advances, the impact of ischemic and haemorrhagic stroke remains huge both in terms of the consequences of disability for individual patients and their families, but also the broader societal cost. In the UK, there are over 100,000 strokes every year, costing the NHS an estimated £3 billion annually, with an additional cost to the economy of £4 billion due to productivity losses, disability and informal care. In the USA, stroke-related costs surpass $50 billion annually. Innovation around neuro-rehabilitation is a crucial component to addressing this burden.
Founded in the U.K. in 2016, Neurofenix’s solution improves the standard of care for survivors of neurological injury. The company is creating better outcomes and recovery for patients by pioneering a new way of delivering neuro-rehabilitation. They offer a clinical-grade and personalised rehab programme, using the Neuroball™device coupled with their healthtech platform to deliver therapeutic activities and enable patients to maximise their rehab, both in the clinic and at home. More information can be found on their website www.neurofenix.com.
We’re proud to be backing Neurofenix in this hugely important work.
More from Sifted here.
More from TechCrunch here.
Return to Updates